Beta Bionics develops the iLet Bionic Pancreas, an automated insulin delivery system for people with type 1 diabetes. The device is designed to reduce day-to-day dosing decisions by automating insulin delivery in coordination with continuous glucose sensing. As a medical-device company, it focuses on simplifying diabetes management for adults and children rather than offering a broad portfolio of unrelated therapies.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 23.2 | — | -16.9 | — |
| Q3 2025 | 27.3 | — | -14.2 | — |
| Q4 2025 | 32.1 | — | -13.5 | — |
| Q1 2026 | 27.6 | — | -21.9 | — |
| Q2 2026 | 32 | 37.8% | -23.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: First Financial Corporation (THFF), Astec Industries, Inc. (ASTE), Daktronics, Inc. (DAKT), SI-BONE, Inc. (SIBN), Navient Corporation (NAVI), Apogee Enterprises, Inc. (APOG)